Key early-stage investing questions: Of all the things you could work on, why this? How does this eventually become a $100 billion business? What do you understand about this that others don’t? What progress have you made in the last week? What are you really great at?

FDA approves Enhertu for all HER-2 positive solid tumors. $DSNKY $AZN That's a bit of history - the first ADC granted a tumor-agnostic label. fda.gov/drugs/resource…

🎉 We made a graphing tool for biological data. And it's free for academics! 📊🧬 Make publication-quality figures in under a minute. No more fiddling with Excel, Prism, ggplot, and PowerPoint. Here's using Sphinx Bio for graphing qPCR data.

Reproducible data analysis: ✅ Handle messy spreadsheets: ✅ Describe your desired analysis in English: ✅ The tool most scientists are missing is something with the flexibility of Excel but the traceability and reproducibility of an enterprise application. Excited for this

DuckCon is coming to Seattle this Thursday, Aug 15. We at MotherDuck are super excited to have the DuckDB crew in our hometown. If you want to hear what's up with everyone's favorite avian Analytics Database, come check out. Sign up here: duckdb.org/2024/08/15/duc…

A biomedical first: spatial biology used to find a lifesaving treatment! Just published nature Deep visual proteomics with #AI leads to effective JAKI treatment for 7 patients with toxic epidermal necrolysis nature.com/articles/s4158… Matthias Mann Lab Thierry Nordmann

Published today! Spatial proteomics reveals JAK/STAT as a target for Toxic Epidermal Necrolysis, an often fatal skin reaction to common medication. We validated our findings in pre-clinical models & successfully treated the first patients worldwide.🧵⬇️ nature.com/articles/s4158…

It all started with ‘Deep Visual Proteomics’ to profile immune cells and keratinocytes across skin diseases from a single 3μm FFPE section each. This cutting-edge technology provided unprecedented insights at cell-type resolution and amazing depth (~5000 proteins!)🥳⬇️

Hub-and-Spoke Biotechs: Nimbus Therapeutics I wrote about how Nimbus's fundamental business model innovation enabled them to make blockbuster drug deals—without selling their entire company. Here's how they built an "evergreen" R&D engine. centuryofbio.com/p/nimbus

The Dawn of Spatial Medicine Until now, spatial omics was used to understand human biology. That changed when it saved lives of patients with a fatal skin condition. In the new Ground Truths, pioneering work by Matthias Mann Lab Thierry Nordmann Max Planck Institute of Biochemistry (MPIB) and an international

What if you could use #AI to find and accurately excise the culprit cells, quantify >5,000 proteins in each, and find a cure for a life-threatening disease that has no effective treatment? That's the beginning of spatial medicine, a momentous medical advance. In the new Ground

Runway is not an AI company. Runway is a media and entertainment company. And I actually think the era of AI companies is over. It's not because AI failed - quite the opposite. It's because AI is becoming infrastructure, as fundamental as electricity or the internet. Calling

"A new standard for understanding disease progression at the single-cell level in human tissue." Unraveling liver disease in Alpha1-antitrypsin deficiency with #DeepVisualProteomics. Another major step forward with spatial omics and #AI. biorxiv.org/content/10.110… Matthias Mann Lab

Grateful for the research highlight in Nature Reviews Drug Discovery Have a look at the summary written by Sarah Crunkhorn, 'JAK inhibition combats adverse skin reaction': nature.com/articles/d4157…. The whole story here 🧵 x.com/NordmannThierr… Matthias Mann Lab nature #DrugRepurposing #AI

🧬🚀 AI-first biology is hitting its stride, and it’s exhilarating to witness! A great read from Nathan Benaich at weekend: press.airstreet.com/p/ai-first-bio… In just five years, we’ve gone from isolated models to generative AI that’s transforming biology from the ground up. With scGPT,

Dual-payload ADCs are rising (fast!) 14 preclinical abstracts on dual payload ADCs at #AACR25 First dual payload ADC in the clinic by the end of April. China leads the way. From Lavinia Woodward (#Beacon)

What a great way to end day 1 of #AACR25. Steven is a 13-year survivor of #PancreaticCancer. One of the original participants on the RUCAPANC trial, now >10 years on Rubraca. That’s me pointing to his survivor lapel! Let's Win Pancreatic Cancer 💜 PanCAN

21,000 announced attendance at #AACR25 . I think all of them are here in the Plenary session to see Kevan Shokat talk about progress in KRAS drug discovery.

Mic-drop presentation at AACR by Cercek et al Non-operative management of MSI-H tumors showing outstanding responses to single agent IO across tumor types. 117 patients with MSI-H tumors 92% RFS at 2 years 35% of patients without ANY adverse events Option for curative intent

Congratulations to Matthias Mann Matthias Mann Lab on election to the prestigious National Academy of Sciences! Your innovative proteomics research earns you this exclusive, elite honor. Your team couldn't be prouder! nasonline.org/news/2025-nas-…